These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 11937593)
1. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. Kalff V; Hicks RJ; Ware RE; Hogg A; Binns D; McKenzie AF J Nucl Med; 2002 Apr; 43(4):492-9. PubMed ID: 11937593 [TBL] [Abstract][Full Text] [Related]
2. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912 [TBL] [Abstract][Full Text] [Related]
3. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan. Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969 [TBL] [Abstract][Full Text] [Related]
4. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer]. Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351 [TBL] [Abstract][Full Text] [Related]
5. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. Kantorová I; Lipská L; Bêlohlávek O; Visokai V; Trubaĉ M; Schneiderová M J Nucl Med; 2003 Nov; 44(11):1784-8. PubMed ID: 14602860 [TBL] [Abstract][Full Text] [Related]
6. The clinical impact of camera-based positron emission tomography imaging in patients with recurrent colorectal cancer. Miller E; Lerman H; Gutman M; Figer A; Livshitz G; Even-Sapir E Invest Radiol; 2004 Jan; 39(1):8-12. PubMed ID: 14701983 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. Langenhoff BS; Oyen WJ; Jager GJ; Strijk SP; Wobbes T; Corstens FH; Ruers TJ J Clin Oncol; 2002 Nov; 20(22):4453-8. PubMed ID: 12431968 [TBL] [Abstract][Full Text] [Related]
9. Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET. van der Veldt AA; Buist MR; van Baal MW; Comans EF; Hoekstra OS; Molthoff CF J Nucl Med; 2008 Dec; 49(12):1936-43. PubMed ID: 18997039 [TBL] [Abstract][Full Text] [Related]
10. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. Hicks RJ; Kalff V; MacManus MP; Ware RE; McKenzie AF; Matthews JP; Ball DL J Nucl Med; 2001 Nov; 42(11):1605-13. PubMed ID: 11696628 [TBL] [Abstract][Full Text] [Related]
11. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. Keidar Z; Haim N; Guralnik L; Wollner M; Bar-Shalom R; Ben-Nun A; Israel O J Nucl Med; 2004 Oct; 45(10):1640-6. PubMed ID: 15471827 [TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Lonneux M; Lawson G; Ide C; Bausart R; Remacle M; Pauwels S Laryngoscope; 2000 Sep; 110(9):1493-7. PubMed ID: 10983949 [TBL] [Abstract][Full Text] [Related]
13. The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project. Fulham MJ; Carter J; Baldey A; Hicks RJ; Ramshaw JE; Gibson M Gynecol Oncol; 2009 Mar; 112(3):462-8. PubMed ID: 19150121 [TBL] [Abstract][Full Text] [Related]
14. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Chung HH; Jo H; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP Gynecol Oncol; 2007 Mar; 104(3):529-34. PubMed ID: 17049971 [TBL] [Abstract][Full Text] [Related]
15. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662 [TBL] [Abstract][Full Text] [Related]
16. FDG PET and PET/CT for colorectal cancer. Delbeke D; Martin WH Methods Mol Biol; 2011; 727():77-103. PubMed ID: 21331930 [TBL] [Abstract][Full Text] [Related]
17. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ogunbiyi OA; Flanagan FL; Dehdashti F; Siegel BA; Trask DD; Birnbaum EH; Fleshman JW; Read TE; Philpott GW; Kodner IJ Ann Surg Oncol; 1997 Dec; 4(8):613-20. PubMed ID: 9416407 [TBL] [Abstract][Full Text] [Related]
18. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. Ramdave S; Thomas GW; Berlangieri SU; Bolton DM; Davis I; Danguy HT; Macgregor D; Scott AM J Urol; 2001 Sep; 166(3):825-30. PubMed ID: 11490227 [TBL] [Abstract][Full Text] [Related]
19. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874 [TBL] [Abstract][Full Text] [Related]
20. Role of (18)F-FDG dual-head gamma-camera coincidence imaging in recurrent or metastatic colorectal carcinoma. Even-Sapir E; Lerman H; Figer A; Rabau M; Livshitz G; Inbar M; Gutman M J Nucl Med; 2002 May; 43(5):603-9. PubMed ID: 11994521 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]